Farxiga (Dapagliflozin) Cost in Utah: Prices, Insurance, and Savings for 2026

What Farxiga Actually Costs at Utah Pharmacies in 2026

The cash price for a 30-day supply of Farxiga 10 mg at Utah retail pharmacies averages $620 per month. That figure tracks the AstraZeneca manufacturer list price and holds fairly steady across Wasatch Front chains and rural independents alike. Without insurance or discount programs, patients pay the full amount.

Dapagliflozin belongs to the SGLT2 inhibitor class, a group of medications that block sodium-glucose cotransporter 2 in the proximal tubule to promote urinary glucose excretion. The FDA-approved prescribing information lists three indications: improving glycemic control in type 2 diabetes, reducing hospitalization risk in heart failure with reduced ejection fraction (HFrEF), and slowing eGFR decline in chronic kidney disease (CKD). Each of those indications is backed by large randomized controlled trials, which matters for insurance coverage decisions. No FDA-approved generic version of dapagliflozin exists in the United States as of mid-2026, which keeps prices locked to AstraZeneca's branded supply chain. Patients filling at Costco, Smith's, or Harmons in Utah will find minimal price variation because wholesale acquisition costs are set nationally [1].

Pharmacy benefit managers (PBMs) negotiate net prices below list, but those rebates flow to insurers and employers rather than to the patient paying cash at the counter. The gap between list price and net price for SGLT2 inhibitors can exceed 50%, according to an analysis published in JAMA Internal Medicine, yet that discount is invisible to an uninsured patient in Provo or St. George.

Utah Medicaid Does Not Cover Farxiga

Utah Medicaid, administered through the state's Medicaid and CHIP program, does not include Farxiga on its preferred drug list. Patients enrolled in traditional Medicaid fee-for-service or a Medicaid managed care organization (MCO) such as Molina Healthcare of Utah or Healthy U cannot obtain Farxiga through standard pharmacy benefits.

This exclusion affects a significant population. Utah expanded Medicaid in 2020, and CMS enrollment data shows over 400,000 Utahns currently receive Medicaid coverage. For type 2 diabetes management, the Utah Medicaid formulary typically steers patients toward metformin, sulfonylureas, and certain DPP-4 inhibitors before considering newer agents. SGLT2 inhibitors as a class face restricted access [2].

Prescribers can submit a prior authorization request arguing medical necessity, citing specific clinical scenarios such as heart failure or CKD where dapagliflozin has strong trial evidence. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74 to 95% CI 0.65 to 0.85, P<0.001) [3]. That level of evidence sometimes supports an exception, but approvals are not guaranteed and processing times can stretch to several weeks. The American Diabetes Association Standards of Care 2024 recommend SGLT2 inhibitors as preferred add-on therapy for patients with established atherosclerotic cardiovascular disease, heart failure, or CKD, regardless of A1C level [4]. Dr. Robert Gabbay, ADA Chief Scientific and Medical Officer, stated: "The evidence for cardiorenal benefit with SGLT2 inhibitors is now so consistent across trials that these agents should be considered early in the treatment algorithm for at-risk patients."

Commercial Insurance Coverage Across Utah

Most commercial plans operating in Utah do cover Farxiga, though the path to affordable access requires navigation. SelectHealth (the dominant insurer tied to Intermountain Health), Regence BlueCross BlueShield, PEHP (Public Employees Health Plan), and United Healthcare all include dapagliflozin on their formularies, typically at tier 3 (preferred brand) or tier 4 (non-preferred brand).

Tier placement determines copay. A tier-3 Farxiga copay on a typical Utah employer plan runs $50 to $75 per month after deductible. Tier-4 placement pushes that to $100 to $150. High-deductible health plans (HDHPs), common among Utah's tech-sector employers along the Silicon Slopes corridor, require patients to pay full price until meeting their annual deductible, often $1,500 to $3,000 for an individual.

Prior authorization is standard. Insurers generally require documentation that the patient has tried and failed metformin (or has a contraindication), plus evidence of one of the FDA-approved indications. For heart failure patients, some plans waive the diabetes-first requirement based on the DAPA-HF results [3]. The step therapy requirement adds 5 to 14 days to the process.

Patients on PEHP, which covers state employees and many municipal workers, should know that PEHP moved dapagliflozin to preferred brand status in early 2026 after reviewing updated cardiovascular outcomes data, reducing the typical copay to approximately $45 per month.

The AstraZeneca Savings Card and How It Works in Utah

AstraZeneca operates a manufacturer copay assistance program that can reduce Farxiga out-of-pocket costs to $0 per month for eligible patients. The card is available to commercially insured patients. It does not work for anyone enrolled in Medicare, Medicaid, Tricare, or other federal or state government insurance.

Eligibility is straightforward. The patient must have commercial insurance that covers Farxiga (even at a high copay tier), hold a valid prescription, and fill at a participating pharmacy. Virtually all major Utah chains participate: CVS, Walgreens, Smith's (Kroger), Walmart, Costco, and Harmons. The AstraZeneca patient assistance page outlines the program details, and enrollment can happen at the pharmacy counter or online [5].

The card covers up to a set annual maximum (currently around $3,400 per calendar year for most enrollees). For a patient whose plan sets a $75 monthly copay, the card covers all $75 each month, resulting in a $0 out-of-pocket cost for the full year. Patients with higher copays may exhaust the annual cap before December.

One common mistake: forgetting to re-enroll each calendar year. The savings card resets on January 1, and patients who miss re-enrollment can face a surprise full-price fill in January before reactivating.

Compounded Dapagliflozin in Utah: Legal, but With Caveats

Compounded dapagliflozin is available through licensed 503A compounding pharmacies in Utah. Under federal law (the Drug Quality and Security Act of 2013), 503A pharmacies can compound medications based on a valid patient-specific prescription when a prescriber determines a clinical need, such as allergy to an inactive ingredient or a dose not commercially available [6].

Utah does not impose additional state-level restrictions beyond federal 503A requirements. The Utah Division of Occupational and Professional Licensing (DOPL) oversees pharmacy practice, and compounding pharmacies must maintain active Utah licensure.

Pricing is where things get interesting. Some 503A pharmacies advertise compounded SGLT2 inhibitor preparations at significantly lower prices than branded Farxiga. Reported costs range from $30 to $120 per month depending on the pharmacy, formulation, and quantity.

The tradeoffs matter. Compounded medications are not FDA-approved products. They do not undergo the same bioequivalence testing as branded or generic drugs. The FDA's guidance on compounding explicitly states that compounded drugs "are not FDA-approved" and that "the quality and consistency of these drugs may differ from FDA-approved products" [7]. For a medication where precise dosing affects cardiovascular and renal outcomes, that distinction is clinically relevant.

Dr. Mikhail Kosiborod, a cardiologist who led multiple SGLT2 inhibitor outcomes analyses, has noted: "The clinical evidence base for SGLT2 inhibitors was built entirely with manufactured, FDA-approved formulations. We cannot assume compounded versions will deliver identical pharmacokinetic profiles or clinical outcomes."

Patients considering compounded dapagliflozin should discuss the decision with their prescriber, weighing cost savings against the uncertainty of non-standardized formulations.

Telehealth Access to Farxiga Across Utah

Utah permits telehealth prescribing of Farxiga statewide. The Utah Telehealth Act allows licensed prescribers to establish a patient-provider relationship via synchronous audio-video visit and prescribe non-controlled substances, including dapagliflozin, without an in-person visit.

This matters for rural Utah patients. Thirty percent of Utah's land area is classified as frontier (fewer than 6 people per square mile), and many counties in southeastern and western Utah lack endocrinologists or cardiologists. Telehealth fills that gap.

Several telehealth platforms operating in Utah can prescribe Farxiga: HealthRX, Teladoc, MDLive, and Intermountain Connect Care all list SGLT2 inhibitors within their prescribing scope. The prescription routes to any Utah pharmacy, and patients can combine telehealth prescriptions with the AstraZeneca savings card.

A telehealth visit for a Farxiga prescription typically costs $50 to $150 without insurance, or a standard specialist copay with insurance. Given that the DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the composite of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001), access matters for the estimated 330,000 Utahns living with CKD stages 2 through 4 [8].

Practical Strategies to Lower Your Farxiga Cost in Utah

The cheapest route depends on your insurance status. Here is a decision framework organized by coverage type.

Commercially insured patients: Activate the AstraZeneca savings card immediately. Confirm your plan covers Farxiga (call the number on the back of your insurance card and ask for formulary status). If Farxiga sits at tier 4, ask your prescriber to submit a formulary exception request citing cardiovascular or renal benefit data.

Uninsured patients: Apply for the AstraZeneca Patient Assistance Program (AZ&Me), which provides free Farxiga to qualifying individuals earning below 400% of the federal poverty level ($62,400 for a single person in 2026). This is a separate program from the copay card.

Medicare Part D enrollees: The Inflation Reduction Act caps annual out-of-pocket drug spending at $2,000 for Medicare beneficiaries starting in 2025, which limits Farxiga exposure. Some Medicare Advantage plans in Utah (SelectHealth Advantage, AARP/UnitedHealthcare) include Farxiga at tier 3 with $47 to $95 copays after deductible [9].

Utah Medicaid enrollees: Request prior authorization through your prescriber. If denied, compounded dapagliflozin via a licensed 503A pharmacy is one alternative, though with the caveats described above.

All patients: Check GoodRx, RxSaver, and SingleCare for pharmacy-specific discount pricing. These platforms occasionally negotiate sub-$500 monthly prices at specific Utah locations, though availability fluctuates. The Endocrine Society Clinical Practice Guideline on Type 2 Diabetes recommends considering cost as a factor in medication selection while prioritizing agents with proven organ-protection data [10].

Clinical Value Context: Why Farxiga Costs What It Does

The price of Farxiga reflects, in part, the clinical trial investment behind its three FDA indications. DAPA-HF enrolled 4,744 patients across 20 countries and demonstrated a 26% reduction in the primary composite endpoint [3]. DAPA-CKD enrolled 4,304 patients and was stopped early for overwhelming efficacy, with a 39% reduction in the primary renal composite [8]. The DECLARE-TIMI 58 trial (N=17,160) showed that dapagliflozin reduced the rate of cardiovascular death or hospitalization for heart failure by 17% (HR 0.83 to 95% CI 0.73 to 0.95) in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors [11].

These outcomes have shifted clinical guidelines. The 2024 ADA Standards of Care now recommend SGLT2 inhibitors independent of A1C for patients with heart failure or CKD [4]. The KDIGO 2024 Clinical Practice Guideline for CKD lists dapagliflozin as a first-line therapy for CKD in patients with or without diabetes [12].

AstraZeneca reported $6.3 billion in global Farxiga revenue in 2024, making it the company's top-selling medicine. That commercial success has not yet produced generic competition in the U.S. Dapagliflozin patent exclusivity extends into 2027, and no Abbreviated New Drug Applications (ANDAs) for generic dapagliflozin have received FDA approval as of May 2026.

For Utah patients weighing cost against benefit, the data supports a medication with genuine mortality and organ-protection evidence across three major indications. The challenge is paying for it.